TP53BP2 and hepatocellular carcinoma: Although EGFR blockage can enhance apoptosis susceptibility in tumor cells [28], our data demonstrate that blocking EGFR tyrosine kinase by erlotinib fails to recover ASPP2 overexpression-induced apoptosis in HCC.